Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist

Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist

Cirrhosis is a liver disease that leads to increased intrahepatic resistance, portal hypertension (PH), and splanchnic hyperemia resulting in ascites, variceal bleeding, and hepatorenal syndrome. Terlipressin, a prodrug that converts to a short half-life vasopressin receptor 1 A (V1a) full agonist [...

Full description

Bibliographic Details
Main Authors: Gerardo M. Castillo, Yao Yao, Rebecca E. Guerra, Han Jiang, Akiko Nishimoto-Ashfield, Alexander V. Lyubimov, Joshua F. Alfaro, Kali A. Striker, Nikolay Buynov, Philipp Schwabl, Elijah M. Bolotin
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Portal hypertension
Cirrhosis
Hepatorenal syndrome
Ascites
Vasopressor
V1a agonist
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223018668

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223018668

Similar Items